RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GRANETTO C
Collezione AOU Città della Salute di Torino

Items : 5

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AO Cuneo
AOU Città della Salute di Torino

Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...

Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. in Tumori / Tumori. 2019 Jun;105(3):243-252. doi: 10.1177/0300891619834126. Epub 2019 Mar 11.

2019
AO Cuneo
AOU Città della Salute di Torino

Tonini G; Bergamo F; Proietti E; Proserpio I; Ballestrero A; Biglietto M; Lucchesi S; Granetto C; Ciuffreda L; Fagnani D; Gemma D; Nasti G; Lonardi S;

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.

2018
AO Cuneo
AOU Città della Salute di Torino

Falcone A; Fontanini G; Boni L; Sensi E; Zagonel V; Masi G; Allegrini G; Granetto C; Buonadonna A; Marmorino F; Tonini G; Zaniboni A; Loupakis F; Ronzoni M; Racca P; Moretto R; Cortesi E; Tomasello G; Lonardi S; Bergamo F; Antoniotti C; Cremolini C; Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; et alii...

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.

2016
AO Cuneo
AOU Città della Salute di Torino

Bustreo S; Ronzoni M; Buonadonna A; Bergamo F; Tomasello G; Tonini G; Allegrini G; Vitello S; Rossini D; Moretto R; Chiara S; Mancini ML; Granetto C; Lonardi S; Masi G; Loupakis F; Cremolini C; Barbara C; Boni L; Falcone A;

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

2015
AO Cuneo
AOU Città della Salute di Torino

Di Donato S; Granetto C; Bonetti A; D'Amico M; Vitello S; Longarini R; Barone C; Tonini G; Spadi R; Zaniboni A; Tomasello G; Cortesi E; Salvatore L; Masi G; Lonardi S; Antoniotti C; Cremolini C; Loupakis F; Boni L; Falcone A;